# Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer

> **NCT03574220** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT03574220
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-19
- **Primary completion:** 2020-03-21
- **Final completion:** 2020-03-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No accrual - closed by PRMC
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574220, "Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03574220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*